Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer

Journal of Nuclear Medicine

Volumn 46, Issue 3, 2005, Pages 400-404

  Van Westreenen, Henderik L ^a   Cobben, David C P ^a   Jager, Pieter L ^a   Van Dullemen, Hendrik M ^a   Wesseling, Jelle ^a   Elsinga, Philip H ^a   Plukker, John Th ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

18F FDG; 18F fluoro 3 deoxy 3 L fluorothymidine; Esophageal cancer; Staging

Indexed keywords

FLUORO 3' DEOXY 3' LEVO FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LINEAR REGRESSION ANALYSIS; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ESOPHAGUS TUMOR; METHODOLOGY; MIDDLE AGED; PILOT STUDY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; DIDEOXYNUCLEOSIDES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 17844371069     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Rice TW. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am. 2000;10:471-485.
2. Clements DM, Bowrey DJ, Havard TJ. The role of staging investigations for oesophago-gastric carcinoma. Eur J Surg Oncol 2004;30:309-312.
3. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Anna Rev Med. 2002;53:89-112.
4. Phay JE, Hussain HB, Moley JF. Strategy for identification of novel glucose transporter family members by using internet-based genomic databases. Surgery. 2000;128:946-951.
5. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
6. 18F-FDG PET. J Nucl Med. 2004;45:980-987.
7. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
8. van Westreenen HL, Heeren PA, Jager PL, van Dullemen HM, Groen H, Plukker JT. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. Ann Surg Oncol. 2003;10:1100-1105.
9. 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med. 2002;43:658-663.
10. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
11. 18F]FLT: portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-169.
12. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
13. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
14. Machulla HJ, Blocther A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[F-18] fluorothymidine ([F-18]FLT). J Radiochem Nucl Chem. 2000;243:843-846.
15. Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med. 1999;26:591-598.
16. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
17. Sobin LH, Wittekind C. TWM Classification of Malignant Tumours. 6th ed. New York, NY: John Wiley & Sons; 2003:60-64.
18. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
19. 18F-FDG PET. J Nucl Med. 2004;45:226-231.
20. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988-994.
21. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-724.
22. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991;266:9032-9038.
23. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
24. Kong XB, Zhu QY, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 1992;36:808-818.
25. Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med. 2001;28:1845-1849.
26. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94:921-928.
27. Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection-prospective study. Radiology. 2003;227: 764-770.
28. 18F-Fluoro-3′-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med. 2003;44:1927-1932.
29. 18F-3′-fluoro- 3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-1690.
30. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407-1412.
31. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032.
32. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
33. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-908.